When Micrograms Are the Limit
An occupational exposure limit of 100 ng/m³ or below — that’s OEB 5 territory. At that threshold, you’re not managing a conventional industrial hygiene problem. You’re handling compounds where a few micrograms of airborne API can trigger a pharmacological response in a healthy operator. Oncologics, hormones, highly potent active pharmaceutical ingredients (HPAPIs) — the development pipeline is full of them, and the number of OEB 5 compounds in active development continues to grow.
The primary engineering response to OEB 5 is not PPE. PPE is the last line of defense. The response is containment — and at OEB 5, containment requirements dictate every piece of equipment in the process train, including the valves.
What OEB 5 Actually Means for Process Equipment
The OEB system classifies compounds by their OEL into bands that define required containment performance. OEB 5 corresponds to OELs ranging from below 1 µg/m³ down to 0.1 µg/m³ or lower. ISPE’s Good Practice Guide on Containment defines performance targets for equipment operating in this band.
For containment equipment — isolators, split butterfly valves, transfer systems — the relevant metric is containment performance measured through surrogate testing. ISPE methodology specifies test conditions that simulate worst-case operations. The target for OEB 5 equipment is typically below 100 ng/m³ averaged over an 8-hour shift, which requires demonstrated equipment performance below 1 µg/m³ under surrogate test conditions.
Valves are among the most consequential components in an OEB 5 process train. Every transfer step — charging, discharging, sampling, transferring between unit operations — is a potential exposure event. Valve design determines whether that step is genuinely contained or only nominally contained on paper.
The Containment Valve Challenge
Conventional valve designs are not OEB 5 capable.
A standard butterfly valve — even a high-quality sanitary model — has a fundamental design limitation for OEB 5 service. When the disc rotates open, the seat face is exposed to the process stream. When it closes, API residue on that face is released into the operator environment. For conventional pharmaceutical products, this is manageable. For an OEB 5 HPAPI with an OEL of 200 ng/m³, it’s an unacceptable exposure pathway.
The problem isn’t specific to butterfly valves. Plug valves with standard packing glands, gate valves with conventional stems, and diaphragm valves with standard bonnet designs all share the same fundamental issue: a continuous pathway from the process side to the ambient environment through the dynamic seal. That pathway can be minimized, but it cannot be eliminated in these designs. At OEB 5, minimized is not sufficient.
Split Butterfly Valve Technology
The split butterfly valve (SBV) — also called an active/passive split valve — is the established solution for OEB 5 powder transfer. The operating principle: the valve consists of two mating halves. The active half mounts on the process vessel or equipment. The passive half mounts on the receiving vessel or containment bag. Docking and undocking are engineered so that API-exposed surfaces never contact the operator environment at any point in the cycle.
When properly designed and operated, split butterfly valves achieve surrogate containment performance in the low µg/m³ range — sufficient for OEB 5 service. The critical design elements are:
- Dual disc design — both halves fully cover their respective flanges before separation
- Seal interface geometry — engineered to prevent powder migration during docking and undocking cycles
- Disc surface finish — minimizes API adhesion at the connection and separation interface
- Interlocking mechanism — prevents premature opening or accidental separation under process conditions
Manufacturing tolerances on split butterfly valves are tight. A misaligned seal, out-of-spec disc flatness, or a worn docking latch can degrade containment performance by orders of magnitude. Dimensional control and manufacturing consistency matter more in this valve class than in nearly any other pharmaceutical fluid handling application.
OEB 5 Containment Across the Process Train
API Dispensing
Dispensing is typically the highest-exposure-risk operation in HPAPI manufacturing. It requires opening a bulk API container, measuring the required quantity, and transferring it to the process — under conditions where the API is most likely to become airborne. The dispensing system must maintain full containment from the moment the container is opened to the moment the transfer is complete.
Valve selection at this step determines whether dispensing occurs inside an isolator, through a validated contained transfer system, or — the worst-case scenario — in open atmosphere with PAPR protection only. The valve is the mechanical enabler of contained dispensing. Without the right valve design, the isolator cannot function as intended.
IBC Transfers and Bin Discharging
IBC transfers in HPAPI manufacturing require contained connections at every transfer point. A drum discharging into a process vessel, a batch transfer between two IBCs — each connection represents a potential exposure event unless the valve system physically prevents it.
Alpha-beta port systems address this at the container interface. The alpha port on the process vessel and the beta port on the receiving container mate without exposing the operator to contents at any point. Critically, both halves are designed so the contaminated surfaces remain shielded through the entire connect-transfer-disconnect sequence. Selecting the right contained transfer technology for each step in the process is a systems engineering decision — not a single valve selection.
Reactor Charging and Sampling
Sampling in HPAPI processes is one of the hardest steps to contain. A standard ball valve sampling port on a reactor requires direct operator interaction with the process stream. Purpose-built OEB 5 sampling valves address this through integrated bag systems, in-line flow cells, or contained sample collection cartridges. The valve design drives the containment outcome at this step just as it does at every other transfer point.
Documentation and Qualification for OEB 5 Valves
OEB 5 containment equipment carries the most demanding qualification requirements in pharmaceutical manufacturing. The standard program includes:
Surrogate containment testing per ISPE methodology, with documented results that can be referenced directly in equipment qualification packages.
Cleaning validation for HPAPI residues, using analytical methods validated to detect at fractions of the OEL — typically requiring HPLC or LC-MS/MS with method detection limits in the low ng/cm² range.
IQ/OQ/PQ documentation with containment performance established as a critical quality attribute, not an ancillary equipment parameter.
Preventive maintenance procedures that actively maintain containment integrity — specifically seal inspection intervals, disc flatness verification, and latch function testing. Deferred maintenance on OEB 5 valves is a containment risk, not just a reliability issue.
Operator training records that demonstrate verified competency in connection, disconnection, and cleaning procedures for each valve type in the process train.
The qualification burden for OEB 5 equipment is substantially higher than for standard pharmaceutical process equipment. Suppliers who operate in this space should provide documentation packages built to support the qualification process — not generic data sheets that transfer the entire qualification burden to the customer.
Why OEB 5 Containment Failures Are Not Recoverable
Operator Health
Exposure to HPAPIs above OEL produces acute pharmacological effects — potentially severe for cytotoxics, hormones, and immunosuppressants. Chronic low-level exposure carries unknown long-term consequences for many compounds currently in development. OSHA, NIOSH, and EU OHS directives all establish employer liability for demonstrable exposure control failures.
Regulatory Consequences
A containment breach in a cGMP facility that results in API cross-contamination of other products or process areas is a critical GMP violation. FDA Form 483 observations and Warning Letters have cited inadequate HPAPI containment controls repeatedly. A product recall triggered by cross-contamination with a potent impurity — at trace concentrations that still exceed acceptable limits — has happened. It is expensive, it is public, and it is avoidable.
Financial Impact
Isolator rebuilds, facility decontamination, unplanned production shutdowns, and worker compensation claims from exposure events are all substantially more expensive than engineering containment correctly at project inception. The cost differential between a properly specified OEB 5 valve system and the response to a containment failure is not close.
Sterivalves and High Containment Engineering
OEB 5 containment systems require a supplier who understands containment performance requirements from the process side — not just valve geometry and material compatibility. At Sterivalves, split butterfly valves and contained transfer systems for HPAPI applications are engineered to meet defined containment performance targets, support full qualification documentation, and integrate cleanly into the process train.
Every containment decision in an OEB 5 facility has a weakest link. The valve and transfer system connection points are where that weakness most often appears — and where exposure events most often occur.
If your facility is processing or planning to process OEB 5 compounds, contact Sterivalves to discuss containment performance requirements, available valve configurations, and what a complete qualification package looks like for your application.
See also: Aseptic Dosing Solutions for Solids: FDA Compliance Guide for Sterile Pharmaceutical Manufacturing
Every containment decision in an OEB 5 facility has a weakest link — and the valve and transfer system connection points are where that weakness most often appears.
Contact Sterivalves to discuss containment performance requirements, available valve configurations, and what a complete qualification package looks like for your OEB 5 application.
OEB 5 containment is not a procurement category — it’s a sustained engineering commitment. The compounds entering pharmaceutical pipelines are more potent, not less. Process equipment, including valves, must match that reality with demonstrated surrogate test performance, rigorous qualification, and technology selected specifically for each transfer step in the process.
Facilities evaluating HPAPI manufacturing capabilities should assess not just isolator and HVAC design, but every connection point in the process train — because that’s where containment is won or lost.
